Operating CF
$4.24B
Capex
-$530M
Free Cash Flow
$3.71B
FCF Margin
+87.5%
Cash flow waterfall for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026
Free cash flow: $3.71B
Cash flow breakdown for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $4.24B | $4.24B |
| Capital Expenditure | -$530M | $3.71B |
| Free Cash Flow | $3.71B | $3.71B |
| Other Investing | -$791M | $2.92B |
| Share Buybacks | -$1.93B | $988M |
| Other Financing & FX | -$169M | $820M |
| Net Cash Increase | $820M | $820M |
- Operating Cash Flow$4.24B
- Capital Expenditure-$530M
- Free Cash Flow$3.71B
- Other Investing-$791M
- Share Buybacks-$1.93B
- Other Financing & FX-$169M
- Net Cash Increase$820M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.